Anita Chugh

Summary

Country: India

Publications

  1. ncbi request reprint Squalene epoxidase as hypocholesterolemic drug target revisited
    Anita Chugh
    New Drug Discovery Research, Department of Pharmacology, Ranbaxy Laboratories Ltd, Plot 20, Sector 18, Udyog Vihar Industrial Area, Gurgaon 122 001, Haryana, India
    Prog Lipid Res 42:37-50. 2003
  2. ncbi request reprint Design, synthesis and activity of novel derivatives of oxybutynin and tolterodine
    Kirandeep Kaur
    Ranbaxy Research Laboratories, New Drug Discovery Research, Department of Medicinal Chemistry, Gurgaon 122 001, Haryana, India
    Bioorg Med Chem Lett 15:2093-6. 2005
  3. doi request reprint RBx 6198: a novel alpha1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia
    Kamna Nanda
    Department of Pharmacology, Ranbaxy Research Laboratories, Plot 20, Sector 18, Gurgaon, 122015, India
    Eur J Pharmacol 607:213-9. 2009
  4. doi request reprint Ratiometric Ca+2 measurement in human recombinant muscarinic receptor subtypes using the Flexstation scanning fluorometer
    Suman Gupta
    Department of Pharmacology, Ranbaxy Research Laboratories, Udyog Vihar, India
    J Recept Signal Transduct Res 29:100-6. 2009
  5. ncbi request reprint Comparative in vivo uroselectivity profiles of anticholinergics, tested in a novel anesthetized rabbit model
    Krishna S Naruganahalli
    Department of Pharmacology, Ranbaxy Research Laboratories, Plot 20, Sector 18, Gurgaon 122 015, India
    Eur J Pharmacol 572:207-12. 2007
  6. ncbi request reprint Synthesis and optimization of novel and selective muscarinic M(3) receptor antagonists
    Naresh Kumar
    Ranbaxy Research Laboratories, New Drug Discovery Research, Department of Medicinal Chemistry, Gurgaon, Haryana 122 001, India
    Bioorg Med Chem Lett 17:5256-60. 2007
  7. ncbi request reprint Statins and myotoxicity: a therapeutic limitation
    Atul Tiwari
    Ranbaxy Research Laboratories, Metabolic and Urology Group, New Drug Discovery Research, Gurgaon 122001, Haryana, India
    Expert Opin Drug Saf 5:651-66. 2006
  8. doi request reprint Discovery of conformationally rigid 3-azabicyclo[3.1.0]hexane-derived dipeptidyl peptidase-IV inhibitors
    Jitendra A Sattigeri
    Department of Medicinal Chemistry, Ranbaxy Research Laboratories, Gurgaon 122001, India
    Bioorg Med Chem Lett 18:4087-91. 2008

Collaborators

  • Atul Tiwari
  • Suman Gupta
  • Krishna S Naruganahalli
  • Naresh Kumar
  • Kamna Nanda
  • Jitendra A Sattigeri
  • Kirandeep Kaur
  • Joseph A Davis
  • Shuchita Singh
  • Kaushal Kishore
  • Vinay S Bansal
  • Murugaiah M S Andappan
  • Suchitra Sharma
  • Sinduja Sundaram
  • Srinivasan Thangathirupathy
  • Anita Mehta
  • Arun D V Silamkoti
  • P K S Sarma
  • Laxminarayan H Hegde
  • Miriyala Bruhaspathy
  • Jang B Gupta
  • Shelly Aeron
  • Shankar J Shetty

Detail Information

Publications8

  1. ncbi request reprint Squalene epoxidase as hypocholesterolemic drug target revisited
    Anita Chugh
    New Drug Discovery Research, Department of Pharmacology, Ranbaxy Laboratories Ltd, Plot 20, Sector 18, Udyog Vihar Industrial Area, Gurgaon 122 001, Haryana, India
    Prog Lipid Res 42:37-50. 2003
    ..Put in perspective squalene epoxidase appears to be undervalued target which merits attention for development of better hypocholesterolemic drugs...
  2. ncbi request reprint Design, synthesis and activity of novel derivatives of oxybutynin and tolterodine
    Kirandeep Kaur
    Ranbaxy Research Laboratories, New Drug Discovery Research, Department of Medicinal Chemistry, Gurgaon 122 001, Haryana, India
    Bioorg Med Chem Lett 15:2093-6. 2005
    ..Novel derivatives of Tolterodine (1) and Oxybutynin (2) have been designed using conformationally restricted azabicyclics as replacement for open-chain amines. The synthesis and structure-activity relationships are presented...
  3. doi request reprint RBx 6198: a novel alpha1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia
    Kamna Nanda
    Department of Pharmacology, Ranbaxy Research Laboratories, Plot 20, Sector 18, Gurgaon, 122015, India
    Eur J Pharmacol 607:213-9. 2009
    ..Taken together all results from preclinical studies, it is suggested that RBx 6198 is a novel alpha(1)-adrenoceptor antagonist that exhibited improved pharmacological profile over tamsulosin in both in vitro and in vivo...
  4. doi request reprint Ratiometric Ca+2 measurement in human recombinant muscarinic receptor subtypes using the Flexstation scanning fluorometer
    Suman Gupta
    Department of Pharmacology, Ranbaxy Research Laboratories, Udyog Vihar, India
    J Recept Signal Transduct Res 29:100-6. 2009
    ..Both the assays exhibited comparable rank order potencies of the standard inhibitors. This study suggests that Ca+2 mobilization assays can be an alternate to radioligand binding assays...
  5. ncbi request reprint Comparative in vivo uroselectivity profiles of anticholinergics, tested in a novel anesthetized rabbit model
    Krishna S Naruganahalli
    Department of Pharmacology, Ranbaxy Research Laboratories, Plot 20, Sector 18, Gurgaon 122 015, India
    Eur J Pharmacol 572:207-12. 2007
    ..Thus rabbits may represent a useful animal model for evaluating putative bladder selective muscarinic receptor antagonists for the treatment of overactive bladder...
  6. ncbi request reprint Synthesis and optimization of novel and selective muscarinic M(3) receptor antagonists
    Naresh Kumar
    Ranbaxy Research Laboratories, New Drug Discovery Research, Department of Medicinal Chemistry, Gurgaon, Haryana 122 001, India
    Bioorg Med Chem Lett 17:5256-60. 2007
    ..Evaluation of these compounds in binding assays revealed that they not only have high affinity for the M(3) receptor but also have high selectivity over the M(2) receptor...
  7. ncbi request reprint Statins and myotoxicity: a therapeutic limitation
    Atul Tiwari
    Ranbaxy Research Laboratories, Metabolic and Urology Group, New Drug Discovery Research, Gurgaon 122001, Haryana, India
    Expert Opin Drug Saf 5:651-66. 2006
    ..The appropriate and judicious use of drugs would substantially reduce the likelihood of developing clinically important myopathy...
  8. doi request reprint Discovery of conformationally rigid 3-azabicyclo[3.1.0]hexane-derived dipeptidyl peptidase-IV inhibitors
    Jitendra A Sattigeri
    Department of Medicinal Chemistry, Ranbaxy Research Laboratories, Gurgaon 122001, India
    Bioorg Med Chem Lett 18:4087-91. 2008
    ..1.0]hexane derivatives at P(2) region of compounds of 2-cyanopyrrolidine class was explored to develop novel DPP-IV inhibitors. The synthesis, structure-activity relationship, and selectivity against related proteases are delineated...